NSABP Members' Area
Password Protected - Access
Limited to NSABP Participating
Institutions Only
NSABP Foundation, Inc.
General NSABP Information
Financial Conflicts of
Interest Policy
Contact the NSABP
Employment
Clinical Trials Information
Clinical Trials Overview
Protocol Chart
Never Say Lost
Treatment Trials Information
Protocol B-51
Protocol B-52
Protocol B-53/S1207
Protocol B-55/BIG 6-13
Prevention Trials Information
Protocol P-1 - BCPT
Protocol P-2 - STAR
To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu
Protocol B-12
A Protocol to Compare L-PAM, 5-FU and Tamoxifen With and Without Adriamycin in the Management of Primary Breast Cancer Patients With Positive Axillary Nodes Whose Tumors are Positive for Estrogen and/or Progesterone Receptors
Specific Aims
To determine whether L-PAM + Adriamycin + 5-FU + tamoxifen (PAFT) is more effective than L-PAM + 5-FU + tamoxifen (PFT) in disease-free survival and survival of patients with one or more positive nodes whose tumors are estrogen-receptor (ER) positive and/or progesterone-receptor (PR) positive.
